Artiva Biotherapeutics, Inc. is an innovative biotechnology company focused on developing next-generation cell therapies for cancer. Leveraging a proprietary platform to enhance natural killer (NK) cell therapies, Artiva is advancing an extensive pipeline targeting a variety of hematologic and solid tumors. The company's commitment to scientific excellence and strategic partnerships positions it as a key player in the dynamic field of immuno-oncology. As it moves forward with clinical development of its promising therapeutic candidates, Artiva aims to transform cancer treatment and significantly improve patient outcomes.
Data last updated: April 11, 2026 at 7:40 AM EDT
Get e-mail RSI alerts when Artiva Biotherapeutics, Inc. Common Stock enters oversold or overbought territory. Free forever.
Add Alert